This content is only available within our institutional offering.
27 Feb 2020
DANONE: COVID-19 aggravating the sales growth issue | NEUTRAL | EUR72 vs. EUR76 (+6%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
DANONE: COVID-19 aggravating the sales growth issue | NEUTRAL | EUR72 vs. EUR76 (+6%)
Danone SA (BN:WBO) | 0 0 2.7% | Mkt Cap: 44,153m
- Published:
27 Feb 2020 -
Author:
Virginie Roumage -
Pages:
3
DANONE - NEUTRAL | EUR72 vs. EUR76 (+6%)
COVID-19 aggravating the sales growth issue
2020 guidance is now for 2-4% organic sales growth…
…and an EBIT margin >15%
Sales expected to rise only3-5% in the mid term
EPS cut by 5% on average over the next three years